The company promoted an insider to take the helm at UnitedHealthcare, its insurance business.
UnitedHealth Group has named the head of its Medicare business as the CEO of its insurance business, succeeding the Brian Thompson, who was shot and killed on Dec. 4 in New York City while walking to attend the company’s annual investor conference.
Tim Noel has been with the company since 2007. A company statement issued today that was quoted by numerous news sources said Noel “brings unparalleled experience to this role with a proven track record and strong commitment to improving how health care works for consumers, physicians, employers, governments and our other partners.”
Noel will be CEO of UnitedHealthcare. UnitedHealth Group also includes Optum, a health services business that includes UnitedHealth's pharmacy benefit manager, Optum Rx. The company had just over $400 billion in revenues last year.
Luigi Mangione, a 26-year-old University of Pennsylvania graduate who grew up in Baltimore, has been charged with murdering Thompson.
Part of the public reaction to Thompson’s killing and Mangione’s arrest was a wave of negative opinions about health insurance and the health insurance companies, much of it expressed on social media.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More